Saturday, January 26, 2008
CHICAGO: Pioglitazone Slows Progression. Part 1
METROPOLIS: Pioglitazone Slows Movement of Carotid Atherosclerosis vs Glimepiride.
November 13, 2006 (Chicago) — Results of a head-to-head examination of 2 antidiabetes drugs have shown an welfare for pioglitazone (Actos, Takeda Pharmaceuticals Compass north America) over glimepiride (Amaryl, Anakena Healthcare) in reaction move of carotid intima-media wideness (CIMT) in patients with type 2 diabetes.
After 18 months of attention, both mean and maximal procession of CIMT was significantly less among patients receiving pioglitazone compared with those on glimepiride.
Results of the Carotid Intima-Media Dimension in Atherosclerosis Using Pioglitazone (CHICAGO) cogitation are published online November 13 in the Daybook of the American language Medical Grouping to coincide with display here at the Denizen Intuition Remembering 2006 Scientific Sessions.
“What this substance is that pioglitazone could be part of a book scheme to manage component cardiovascular risk in patients with type 2 diabetes,” Theodore Mazzone, MD, from the Educational institution of IL Complex of Drug, in INSTANCE OFcity, moneyman detective for the competition, told a wardrobe league here.
The concentration was funded by Takeda Pharmaceuticals U.S. USA Inc.
CIMT is a symbol of coronary atherosclerosis and predicts subsequent cardiovascular events, the authors write.
Both pioglitazone, a thiazolidinedione, and glimepiride, a sulfonylurea, are antidiabetic agents and about equally efficacious in chemical reaction rakehell glucose but work through different mechanisms, Dr.
Mazzone said.
Pioglitazone, though, has other effects that might be expected to translate into possibility reaction of cardiovascular risk, including reductions in markers of systemic redness and fatty-acid levels, he noted.
Thiazolidinediones have also been shown to reduce atherosclerotic patch in animals independently of glucose or lipid levels.
This is a part of article CHICAGO: Pioglitazone Slows Progression. Part 1 Taken from "Generic Amaryl (Glimepiride) Information" Information Blog
Labels: pharmacology
